Treatment of Primary Biliary Cholangitis including Transplantation.
FXR agonoist
Obeticholic acid
PBC treatment
Ursodeoxycholic acid
Journal
Clinics in liver disease
ISSN: 1557-8224
Titre abrégé: Clin Liver Dis
Pays: United States
ID NLM: 9710002
Informations de publication
Date de publication:
02 2024
02 2024
Historique:
medline:
13
11
2023
pubmed:
10
11
2023
entrez:
9
11
2023
Statut:
ppublish
Résumé
Ursodeoxycholic acid (UDCA) is the first-line treatment of primary biliary cholangitis (PBC). Long-term UDCA use significantly reduces progression to cirrhosis. UDCA improves liver enzymes and transplant-free survival rates. Despite the association between PBC and hyperlipidemia, treatment is indicated under specific circumstances with statins and fibrates being safe options. Osteoporosis, which is frequently seen, is usually managed based on data from postmenopausal women. Sicca syndrome is treated similarly to its standalone condition with the use of hydroxypropyl methylcellulose eye drops and anticholinergic drugs.
Identifiants
pubmed: 37945152
pii: S1089-3261(23)00083-1
doi: 10.1016/j.cld.2023.07.003
pii:
doi:
Substances chimiques
Ursodeoxycholic Acid
724L30Y2QR
Fibric Acids
0
Cholagogues and Choleretics
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103-114Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.